Table 1.
Analysis of the population baseline and the hormones in patients with thyroid nodules and no nodules among the diabetic and non-diabetic participants
| Influencing factors | Diabetic patients (n = 43) | Non-diabetic patients (n = 799) | ||||
|---|---|---|---|---|---|---|
|
| ||||||
| Non-thyroid nodule patients (n = 8) | Thyroid nodule patients (n = 35) | P | Non thyroid nodule patients (n = 234) | Thyroid nodule patients (n = 565) | P | |
| Age | ||||||
| < 60 years old | 6 (40.0) | 9 (60.0) | 0.0083 | 144 (33.2) | 290 (66.8) | 0.0084 |
| ≥ 60 years old | 2 (7.1) | 26 (92.9) | 90 (24.7) | 275 (75.3) | ||
| Gender | ||||||
| Male | 4 (33.3) | 8 (66.7) | 0.1225 | 108 (37.4) | 181 (62.6) | 0.0002 |
| Female | 4 (12.9) | 27 (87.1) | 126 (24.7) | 384 (75.3) | ||
| 25-hydroxyvitamin D | 37.46 ± 8.96 | 36.48 ± 10.01 | 0.8007 | 38.45 ± 10.96 | 39.14 ± 11.06 | 0.4235 |
| LH | 15.76 ± 12.2 | 18.63 ± 12.41 | 0.5580 | 11.57 ± 11.42 | 16.17 ± 13.29 | < 0.0001 |
| FSH | 35.35 ± 33.13 | 45.51 ± 28.08 | 0.3766 | 25.46 ± 28.61 | 37.47 ± 33.2 | < 0.0001 |
| Testosterone | 6.99 ± 7.02 | 4.96 ± 8.96 | 0.5530 | 7.84 ± 8.6 | 5.76 ± 7.98 | 0.0011 |
| Estradiol | 123.94 ± 70.33 | 92.3 ± 34.01 | 0.2513 | 169.92 ± 248.8 | 161.79 ± 221.74 | 0.6649 |
| TSH | 2.65 ± 0.62 | 2.18 ± 1.14 | 0.2644 | 2.78 ± 1.94 | 2.4 ± 1.49 | 0.0071 |
| Thyroxine | 104.23 ± 18.97 | 117.7 ± 19.87 | 0.0888 | 106.04 ± 20.91 | 109.37 ± 20.37 | 0.0372 |
| T3 | 1.31 ± 0.24 | 1.39 ± 0.22 | 0.3849 | 1.44 ± 0.27 | 1.42 ± 0.23 | 0.2107 |
| Creatinine | 67.25 ± 8.15 | 71.23 ± 36.22 | 0.5598 | 67.33 ± 11.14 | 65.04 ± 11.64 | 0.0103 |
| GOT | 29.13 ± 11.14 | 26.51 ± 12.46 | 0.5895 | 28.8 ± 15.56 | 25.31 ± 12.17 | 0.0023 |
| GPT | 41.75 ± 30.27 | 25.31 ± 17.01 | 0.1762 | 26.91 ± 21.21 | 21.98 ± 14.66 | 0.0013 |
| Insulin | 58.39 ± 45.08 | 68.48 ± 64.74 | 0.6792 | 46.76 ± 43.12 | 40.14 ± 28.7 | 0.0316 |